KRYS

Krystal Biotech, Inc.

109.34 USD
+1.33 (+1.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Krystal Biotech, Inc. stock is down -16.13% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Jan 18:34 16 Feb, 2024 135.00 CALL 65 9
12 Jan 19:44 19 Jan, 2024 130.00 CALL 105 15
16 Jan 16:20 20 Dec, 2024 190.00 PUT 5 0
16 Jan 17:29 20 Dec, 2024 190.00 PUT 51 0
25 Jan 19:15 16 Feb, 2024 125.00 CALL 125 879
29 Jan 20:24 20 Dec, 2024 195.00 PUT 53 0
15 Feb 16:46 15 Mar, 2024 100.00 CALL 270 0
16 Feb 19:35 16 Aug, 2024 90.00 PUT 30 0
16 Feb 19:36 16 Aug, 2024 85.00 PUT 35 0
22 Feb 16:02 17 May, 2024 130.00 CALL 50 40

About Krystal Biotech, Inc.

Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.